E. Garin and B. Denizot, 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma, Nuclear Medicine Communications, vol.25, issue.10, pp.1007-1020, 2004.
DOI : 10.1097/00006231-200410000-00004

P. Gunven, Liver embolizations in oncology: A review, Medical Oncology, vol.182, issue.Suppl 1, pp.1-11, 2008.
DOI : 10.1007/s12032-007-0039-3

U. O. Hafeli and G. J. Pauer, Fibrin glue system for adjuvant brachytherapy of brain tumors with 188Re and 186Re-labeled microspheres, European Journal of Pharmaceutics and Biopharmaceutics, vol.65, issue.3, pp.282-290, 2007.
DOI : 10.1016/j.ejpb.2006.10.016

G. E. Hepatocellulaire, A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire, N Engl J Med, vol.332, pp.1256-61, 1995.

P. Hilgard and M. Hamami, Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, vol.74, issue.5, pp.1741-1750, 2010.
DOI : 10.1002/hep.23944

S. Jonas and W. O. Bechstein, Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis, Hepatology, vol.33, issue.5, pp.1080-1086, 2001.
DOI : 10.1053/jhep.2001.23561

Z. Kan and P. A. Mccuskey, Role of Kupffer Cells in Iodized Oil Embolization, Investigative Radiology, vol.29, issue.11, pp.990-993, 1994.
DOI : 10.1097/00004424-199411000-00007

W. T. Kassahun and J. Fangmann, Liver resection and transplantation in the management of hepatocellular carcinoma: a review, Exp Clin Transplant, vol.4, issue.2, pp.549-58, 2006.

K. Knesaurek and J. Machac, Y Therapy of Liver Cancer, Technology in Cancer Research & Treatment, vol.48, issue.3, pp.253-62, 2010.
DOI : 10.1177/153303461000900304

V. Mazzaferro and E. Regalia, Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis, New England Journal of Medicine, vol.334, issue.11, pp.693-702, 1996.
DOI : 10.1056/NEJM199603143341104

J. P. Mcwilliams and S. Yamamoto, Percutaneous Ablation of Hepatocellular Carcinoma: Current Status, Journal of Vascular and Interventional Radiology, vol.21, issue.8, pp.204-217, 2010.
DOI : 10.1016/j.jvir.2009.11.025

F. Mevellec and N. Lepareur, Chelated Hydrazido(3???)rhenium(V) Complexes:?? On the Way to the Nitrido???M(V) Core (M = Tc, Re), Inorganic Chemistry, vol.41, issue.6, pp.1591-1598, 2002.
DOI : 10.1021/ic0110979

H. Nagamatsu and M. Hiraki, Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis, Alimentary Pharmacology & Therapeutics, vol.249, issue.4, pp.543-50, 2010.
DOI : 10.1111/j.1365-2036.2010.04379.x

H. Nordenstedt and D. L. White, The changing pattern of epidemiology in hepatocellular carcinoma, Digestive and Liver Disease, vol.42, issue.3, pp.206-220, 2010.
DOI : 10.1016/S1590-8658(10)60507-5

H. Ohishi and H. Uchida, Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents., Radiology, vol.154, issue.1, pp.25-34, 1985.
DOI : 10.1148/radiology.154.1.2981114

J. L. Raoul and P. Bourguet, Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases., Radiology, vol.168, issue.2, pp.541-546, 1988.
DOI : 10.1148/radiology.168.2.2839866

J. L. Raoul and D. Guyader, Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support, J Nucl Med, vol.35, issue.11, pp.1782-1789, 1994.

J. L. Raoul and D. Guyader, Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma., Hepatology, vol.26, issue.5, pp.1156-61, 1997.
DOI : 10.1053/jhep.1997.v26.pm0009362356

M. Ravaioli and G. L. Grazi, Liver Transplantation for Hepatocellular Carcinoma: Results of Down-Staging in Patients Initially Outside the Milan Selection Criteria, American Journal of Transplantation, vol.12, issue.12, pp.2547-57, 2008.
DOI : 10.1111/j.1600-6143.2008.02409.x

R. B. Rindani and T. J. Hugh, 131I lipiodol therapy for unresectable hepatocellular carcinoma, ANZ Journal of Surgery, vol.72, issue.3, pp.210-214, 2002.
DOI : 10.1007/s005340050179

S. Sahara and N. Kawai, Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma, Japanese Journal of Radiology, vol.74, issue.S6, pp.362-370, 2010.
DOI : 10.1007/s11604-010-0436-y

R. Salem and R. J. Lewandowski, Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival, Journal of Vascular and Interventional Radiology, vol.16, issue.12, pp.1627-1666, 2005.
DOI : 10.1097/01.RVI.0000184594.01661.81

S. W. Shin, The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma, Korean Journal of Radiology, vol.10, issue.5, pp.425-459, 2009.
DOI : 10.3348/kjr.2009.10.5.425

S. Wallace and C. H. Carrasco, Hepatic artery infusion and chemoembolization in the management of liver metastases, Cardiovascular and Interventional Radiology, vol.260, issue.7, pp.153-60, 1990.
DOI : 10.1007/BF02575467

S. J. Wang and W. Y. Lin, Radiolabelling of lipiodol with generator-produced 188Re for hepatic tumor therapy, Applied Radiation and Isotopes, vol.47, issue.3, pp.267-71, 1996.
DOI : 10.1016/0969-8043(95)00300-2

S. J. Wang and W. Y. Lin, Hepatic artery injection of Yttrium-90-lipiodol: biodistribution in rats with hepatoma, J Nucl Med, vol.37, issue.2, pp.332-337, 1996.

M. A. Worns and P. R. Galle, Future perspectives in hepatocellular carcinoma, Digestive and Liver Disease, vol.42, issue.3, pp.302-311, 2010.
DOI : 10.1016/S1590-8658(10)60521-X

G. Wunderlich and J. Pinkert, Labeling and biodistribution of different particle materials for radioembolization therapy with 188Re, Applied Radiation and Isotopes, vol.62, issue.5, pp.745-50, 2005.
DOI : 10.1016/j.apradiso.2004.11.003

K. C. Xu and L. Z. Niu, Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma, World Journal of Gastroenterology, vol.15, issue.29, pp.3664-3673, 2009.
DOI : 10.3748/wjg.15.3664

J. D. Yang and L. R. Roberts, Hepatocellular carcinoma: a global view, Nature Reviews Gastroenterology & Hepatology, vol.150, issue.8, pp.448-58, 2010.
DOI : 10.1038/nrgastro.2010.100

F. Y. Yao and L. Ferrell, Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival, Hepatology, vol.33, issue.6, pp.1394-403, 2001.
DOI : 10.1053/jhep.2001.24563

A. R. Haldemann, Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability, J Nucl Med, vol.36, pp.403-410, 1995.

A. R. Mehdipour and M. Hamidi, Brain drug targeting: a computational approach for overcoming blood???brain barrier, Drug Discovery Today, vol.14, issue.21-22, pp.1030-1036, 2009.
DOI : 10.1016/j.drudis.2009.07.009

A. L. Sundberg, Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211 At-EGF, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.10, pp.1348-1356, 2003.
DOI : 10.1007/s00259-003-1308-9

B. Chini, Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue, British Journal of Cancer, vol.89, issue.5, pp.930-936, 2003.
DOI : 10.1038/sj.bjc.6601189

S. Shen, M. B. Khazaeli, G. Y. Gillespie, and V. L. Alvarez, Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice, Journal of Neuro-Oncology, vol.21, issue.2, pp.113-119, 2005.
DOI : 10.1007/s11060-004-0890-4

Y. C. Patel and C. B. Srikant, Somatostatin Receptors, Trends in Endocrinology and Metabolism, vol.8, issue.10
DOI : 10.1016/S1043-2760(97)00168-9

M. Cammalleri, Functional effects of somatostatin receptor 1 activation on synaptic transmission in the mouse hippocampus, Journal of Neurochemistry, vol.12, issue.6, pp.1466-1477, 2009.
DOI : 10.1111/j.1471-4159.2009.06423.x

J. C. Reubi, W. Lang, R. Maurer, J. W. Koper, and S. W. Lamberts, Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system, Cancer Res, vol.47, pp.5758-5764, 1987.

F. Barbieri, via a Phosphotyrosine Phosphatase-??-Dependent Inhibition of Extracellularly Regulated Kinase-1/2, Endocrinology, vol.149, issue.9, pp.4736-4746, 2008.
DOI : 10.1210/en.2007-1762

K. Lamszus, W. Meyerhof, and M. Westphal, Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas, Journal of Neuro-Oncology, vol.35, issue.3, pp.353-364, 1997.
DOI : 10.1023/A:1005893223090

J. C. Reubi, Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors, Am J Pathol, vol.134, pp.337-344, 1989.

Y. C. Patel, Somatostatin and Its Receptor Family, Frontiers in Neuroendocrinology, vol.20, issue.3, pp.157-198, 1999.
DOI : 10.1006/frne.1999.0183

M. Pawlikowski and G. Melen-mucha, Somatostatin analogs ??? from new molecules to new applications, Current Opinion in Pharmacology, vol.4, issue.6, pp.608-613, 2004.
DOI : 10.1016/j.coph.2004.06.010

A. Merlo, Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas, Clin Cancer Res, vol.5, pp.1025-1033, 1999.

A. Otte, DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy, Eur J Nucl Med, vol.24, pp.792-795, 1997.

A. Otte, Yttrium-90-labelled somatostatin-analogue for cancer treatment, The Lancet, vol.351, issue.9100, pp.417-418, 1998.
DOI : 10.1016/S0140-6736(05)78355-0

D. Beutler, -octreotide radiopeptide brachytherapy, Cancer, vol.19, issue.1-2, pp.869-873, 2005.
DOI : 10.1002/cncr.20822

URL : https://hal.archives-ouvertes.fr/hal-00316046

L. Bodei, Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.31, issue.7, pp.1038-1046, 2004.
DOI : 10.1007/s00259-004-1571-4

S. Hofer, Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC), Swiss Med Wkly, vol.131, pp.640-644, 2001.

T. Schumacher, Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study, European Journal of Nuclear Medicine and Molecular Imaging, vol.29, issue.4, pp.486-493, 2002.
DOI : 10.1007/s00259-001-0717-x

M. De-jong, Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy, European Journal of Nuclear Medicine, vol.265, issue.4, pp.368-371, 1997.
DOI : 10.1007/BF00881807

D. Heute, Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC, Journal of Nuclear Medicine, vol.51, issue.3, pp.397-400, 2010.
DOI : 10.2967/jnumed.109.072819

G. Ting, C. H. Chang, and H. Wang, Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy, Anticancer Res, vol.29, pp.4107-4118, 2009.
DOI : 10.1142/9789814520652_0038

R. Salem, Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes, Gastroenterology, vol.138, issue.1, pp.52-64, 2010.
DOI : 10.1053/j.gastro.2009.09.006

E. Garcion, A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats, Molecular Cancer Therapeutics, vol.5, issue.7, pp.1710-1722, 2006.
DOI : 10.1158/1535-7163.MCT-06-0289

URL : https://hal.archives-ouvertes.fr/hal-00358958

A. Beduneau, Pegylated Nanocapsules Produced by an Organic Solvent-Free Method: Evaluation of their Stealth Properties, Pharmaceutical Research, vol.134, issue.109, pp.2190-2199, 2006.
DOI : 10.1007/s11095-006-9061-y

B. J. Kruchko, P. Mccarthy, J. A. Rajaraman, S. Schwartzbaum, B. Sadetzki et al., Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium, Cancer, vol.113, pp.1953-1968, 2008.

D. Allgeier, J. G. Lacombe, E. Cairncross, R. O. Eisenhauer, and . Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-996, 2005.

P. D. Hynynen, D. M. Senter, E. A. Peereboom, and . Neuwelt, Chemotherapy delivery issues in central nervous system malignancy: a reality check, J Clin Oncol, vol.25, pp.2295-2305, 2007.

J. C. Gratzl, R. Reubi, J. Maecke, A. Mueller-brand, and . Merlo, Local injection of the 90Y- labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study, Eur J Nucl Med Mol Imaging, vol.29, pp.486-493, 2002.

D. D. Zhao, M. R. Bigner, and . Zalutsky, Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results, 2006.

M. Puig, A. Iglesias, M. Hernandez, L. Ramos, N. Rodriquez et al., Phase I singledose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma, Cancer Biol Ther, vol.7, pp.333-339, 2008.

S. D. Caruthers, S. A. Wickline, and G. M. Lanza, Nanotechnological applications in medicine, Current Opinion in Biotechnology, vol.18, issue.1, pp.26-30, 2007.
DOI : 10.1016/j.copbio.2007.01.006

B. Heurtault, P. Saulnier, B. Pech, J. E. Proust, and J. P. Benoit, A novel phase inversionbased process for the preparation of lipid nanocarriers, Pharmaceutical Research, vol.19, issue.6, pp.875-880, 2002.
DOI : 10.1023/A:1016121319668

P. Racineux, J. P. Diot, T. Benoit, and . Urban, Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel, Eur J Pharm Biopharm, vol.73, pp.239-246, 2009.

J. P. Lamprecht and . Benoit, In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel, Int J Pharm, vol.344, pp.143-149, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00258366

. Pitard, The encapsulation of DNA molecules within biomimetic lipid nanocapsules, Biomaterials, vol.30, pp.3197-3204, 2009.

E. Garcion, A. Lamprecht, B. Heurtault, A. Paillard, A. Aubert-pouessel et al., A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats, Molecular Cancer Therapeutics, vol.5, issue.7, pp.1710-1722, 2006.
DOI : 10.1158/1535-7163.MCT-06-0289

URL : https://hal.archives-ouvertes.fr/hal-00358958

A. Lamprecht and J. P. Benoit, Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition, Journal of Controlled Release, vol.112, issue.2, pp.208-213, 2006.
DOI : 10.1016/j.jconrel.2006.02.014

E. Roger, F. Lagarce, E. Garcion, and J. P. Benoit, Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells, European Journal of Pharmaceutical Sciences, vol.40, issue.5, pp.422-429, 2010.
DOI : 10.1016/j.ejps.2010.04.015

A. Paillard, F. Hindre, C. Vignes-colombeix, J. P. Benoit, and E. Garcion, The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability, Biomaterials, vol.31, issue.29, pp.7542-7554, 2010.
DOI : 10.1016/j.biomaterials.2010.06.024

E. Allard, F. Hindre, C. Passirani, L. Lemaire, N. Lepareur et al., 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas, European Journal of Nuclear Medicine and Molecular Imaging, vol.112, issue.10, pp.1838-1846, 2008.
DOI : 10.1007/s00259-008-0735-z

URL : https://hal.archives-ouvertes.fr/inserm-00343438

S. Vinchon-petit, D. Jarnet, A. Paillard, J. P. Benoit, E. Garcion et al., In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy, Journal of Neuro-Oncology, vol.28, issue.2, pp.195-205
DOI : 10.1007/s11060-009-0012-4

J. A. Weydert, T. T. Longmate, D. R. Huang, L. W. Spitz, J. J. Oberley et al., Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses, 2003.

W. F. Morgan and M. B. Sowa, Non-targeted bystander effects induced by ionizing radiation, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.616, issue.1-2, pp.159-164, 2007.
DOI : 10.1016/j.mrfmmm.2006.11.009

F. Pasi, A. Facoetti, and R. Nano, IL-8 and IL-6 bystander signalling in human glioblastoma cells exposed to gamma radiation, Anticancer Res, vol.30, pp.2769-2772, 2010.

L. Galluzzi, M. C. Maiuri, I. Vitale, H. Zischka, M. Castedo et al., Cell death modalities: classification and pathophysiological implications, Cell Death and Differentiation, vol.94, issue.7, pp.1237-1243, 2007.
DOI : 10.1038/sj.cdd.4402148

S. C. Formenti and S. Demaria, Systemic effects of local radiotherapy, The Lancet Oncology, vol.10, issue.7, pp.718-726, 2009.
DOI : 10.1016/S1470-2045(09)70082-8

S. Andre, T. Delaloge, G. Tursz, L. Kroemer, and . Zitvogel, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat Med, vol.13, pp.1050-1059, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00316924

P. J. Coates, J. K. Rundle, S. A. Lorimore, and E. G. Wright, Indirect Macrophage Responses to Ionizing Radiation: Implications for Genotype-Dependent Bystander Signaling, Cancer Research, vol.68, issue.2, pp.450-456, 2008.
DOI : 10.1158/0008-5472.CAN-07-3050

M. Larsson, J. F. Fonteneau, and N. Bhardwaj, Dendritic cells resurrect antigens from dead cells, Trends in Immunology, vol.22, issue.3, pp.141-148, 2001.
DOI : 10.1016/S1471-4906(01)01860-9

J. H. Hong, C. S. Chiang, I. L. Campbell, J. R. Sun, H. R. Withers et al., Induction of acute phase gene expression by brain irradiation, International Journal of Radiation Oncology*Biology*Physics, vol.33, issue.3, pp.619-626, 1995.
DOI : 10.1016/0360-3016(95)00279-8

J. H. Hong, C. S. Chiang, C. Y. Tsao, P. Y. Lin, W. H. Mcbride et al., Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation, Int J Radiat Biol, vol.75, pp.1421-1427, 1999.

H. Ishihara, K. Tsuneoka, A. B. Dimchev, and M. Shikita, Induction of the Expression of the Interleukin-1b Gene in Mouse Spleen by Ionizing Radiation, Radiation Research, vol.133, issue.3, pp.321-326, 1993.
DOI : 10.2307/3578216

M. Iwamoto, Y. P. Pervan, R. E. Liao, M. Xu, G. K. Koski et al., A sense of danger from radiation Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer, Radiat Res Oncogene, vol.162, issue.27, pp.1-19200, 2004.

N. L. Bennewitz and J. E. Babensee, The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen, Biomaterials, vol.26, issue.16, pp.2991-2999, 2005.
DOI : 10.1016/j.biomaterials.2004.08.023

R. Hunter, F. Strickland, and F. Kezdy, The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance, J Immunol, vol.127, pp.1244-1250, 1981.

S. T. Reddy, M. A. Swartz, and J. A. , Targeting dendritic cells with biomaterials: developing the next generation of vaccines, Trends in Immunology, vol.27, issue.12, pp.573-579, 2006.
DOI : 10.1016/j.it.2006.10.005

M. Yoshida and J. E. Babensee, Poly(lactic-co-glycolic acid) enhances maturation of human monocyte-derived dendritic cells, Journal of Biomedical Materials Research, vol.2, issue.1, pp.45-54, 2004.
DOI : 10.1002/jbm.a.30131

N. Lepareur and N. N. , A kit formulation for the labelling of lipiodol with generator-produced188Re, Journal of Labelled Compounds and Radiopharmaceuticals, vol.9, issue.12, pp.857-867, 2004.
DOI : 10.1002/jlcr.863

V. R. Recinos, B. M. Tyler, K. Bekelis, S. B. Sunshine, A. Vellimana et al., Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives, Neurosurgery Cell Mol Life Sci, vol.66, issue.56, pp.530-537, 1999.

R. Bhat and L. Steinman, Innate and Adaptive Autoimmunity Directed to the Central Nervous System, Neuron, vol.64, issue.1, pp.123-132, 2009.
DOI : 10.1016/j.neuron.2009.09.015

P. A. Carpentier and T. D. Palmer, Immune Influence on Adult Neural Stem Cell Regulation and Function, Neuron, vol.64, issue.1, pp.79-92, 2009.
DOI : 10.1016/j.neuron.2009.08.038

URL : http://doi.org/10.1016/j.neuron.2009.08.038

J. M. Adams and A. Strasser, Is Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones?, Cancer Research, vol.68, issue.11, pp.4018-4021, 2008.
DOI : 10.1158/0008-5472.CAN-07-6334

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.465.7556

M. Diehn and M. F. Clarke, Cancer Stem Cells and Radiotherapy: New Insights Into Tumor Radioresistance, JNCI Journal of the National Cancer Institute, vol.98, issue.24, pp.1755-1757, 2006.
DOI : 10.1093/jnci/djj505

URL : http://jnci.oxfordjournals.org/cgi/content/short/98/24/1755

A. Dimeco and . Vescovi, Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma, Cancer Res, vol.64, pp.7011-7021, 2004.

W. Christopher, J. K. Zhang, H. A. Park, and . Fine, Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines, Cancer Cell, vol.9, pp.391-403, 2006.

P. B. Cusimano and . Dirks, Identification of human brain tumour initiating cells, Nature, vol.432, pp.396-401, 2004.

S. Bao, Q. Wu, R. E. Mclendon, Y. Hao, Q. Shi et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.8, issue.7120, pp.756-760, 2006.
DOI : 10.1038/nature05236

M. Dean, T. Fojo, and S. Bates, Tumour stem cells and drug resistance, Nature Reviews Cancer, vol.22, issue.4, pp.275-284, 2005.
DOI : 10.1006/gyno.2002.6762

M. Verheij and H. Bartelink, Radiation-induced apoptosis, Cell and Tissue Research, vol.301, issue.1, pp.133-142, 2000.
DOI : 10.1007/s004410000188

F. Lefranc, J. Brotchi, and R. Kiss, Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis, Journal of Clinical Oncology, vol.23, issue.10, pp.2411-2422, 2005.
DOI : 10.1200/JCO.2005.03.089

S. Vinchon-petit, D. Jarnet, A. Paillard, J. P. Benoit, E. Garcion et al., In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy, Journal of Neuro-Oncology, vol.28, issue.2, pp.195-205, 2010.
DOI : 10.1007/s11060-009-0012-4

S. Ali and J. F. Curtin, Inflammatory and Anti-glioma Effects of an Adenovirus Expressing Human Soluble Fms-like Tyrosine Kinase 3 Ligand (hsFlt3L): Treatment with hsFlt3L Inhibits Intracranial Glioma Progression, Molecular Therapy, vol.10, issue.6, pp.1071-84, 2004.
DOI : 10.1016/j.ymthe.2004.08.025

R. F. Barth and B. Kaur, Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas, Journal of Neuro-Oncology, vol.10, issue.Suppl 1, pp.299-312, 2009.
DOI : 10.1007/s11060-009-9875-7

S. K. Batra and S. Castelino-prabhu, Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene, Cell Growth Differ, vol.6, issue.10, pp.1251-1260, 1995.

S. H. Bigner and P. A. Humphrey, Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts, Cancer Res, vol.50, issue.24, pp.8017-8039, 1990.

J. A. Boockvar and D. Kapitonov, Constitutive EGFR signaling confers a motile phenotype to neural stem cells, Molecular and Cellular Neuroscience, vol.24, issue.4, pp.1116-1146, 2003.
DOI : 10.1016/j.mcn.2003.09.011

A. Clavreul and M. Delhaye, Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model, Journal of Neuro-Oncology, vol.50, issue.1, pp.9-17, 2006.
DOI : 10.1007/s11060-005-9115-8

L. Frederick and X. Y. Wang, Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas, Cancer Res, vol.60, issue.5, pp.1383-1390, 2000.

A. B. Heimberger and R. Hlatky, Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients, Clinical Cancer Research, vol.11, issue.4, pp.1462-1468, 2005.
DOI : 10.1158/1078-0432.CCR-04-1737

H. S. Huang and M. Nagane, The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling, Journal of Biological Chemistry, vol.272, issue.5, pp.2927-2962, 1997.
DOI : 10.1074/jbc.272.5.2927

G. Lammering and T. H. Hewit, Inhibition of the Type III Epidermal Growth Factor Receptor Variant Mutant Receptor by Dominant-Negative EGFR-CD533 Enhances Malignant Glioma Cell Radiosensitivity, Clinical Cancer Research, vol.10, issue.19, pp.6732-6775, 2004.
DOI : 10.1158/1078-0432.CCR-04-0393

G. Lammering and T. H. Hewit, EGFRvIII-mediated radioresistance through a strong cytoprotective response, Oncogene, vol.22, issue.36, pp.5545-53, 2003.
DOI : 10.1038/sj.onc.1206788

G. Lammering and K. Valerie, Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance, Radiotherapy and Oncology, vol.72, issue.3, pp.267-73, 2004.
DOI : 10.1016/j.radonc.2004.07.004

T. A. Libermann and H. R. Nusbaum, Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin, Nature, vol.4, issue.5998, pp.144-151, 1985.
DOI : 10.1038/313144a0

S. D. Lyman and L. James, Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells, Blood, vol.83, issue.10, pp.2795-801, 1994.

D. H. Lynch and A. Andreasen, Flt3 ligand induces tumor regression and antitumor immune responses in vivo, Nature Medicine, vol.9, issue.6, pp.625-656, 1997.
DOI : 10.1016/0925-5710(95)00389-A

E. Maraskovsky and K. Brasel, Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified, Journal of Experimental Medicine, vol.184, issue.5, pp.1953-62, 1996.
DOI : 10.1084/jem.184.5.1953

R. B. Montgomery and J. Guzman, Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters ??-Tubulin Isotype Expression, Journal of Biological Chemistry, vol.275, issue.23, pp.17358-63, 2000.
DOI : 10.1074/jbc.M000966200

D. B. Paul and R. F. Barth, B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity, Gene Therapy, vol.7, issue.12, pp.993-1002, 2000.
DOI : 10.1038/sj.gt.3301209

M. W. Pedersen and V. Tkach, Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility, International Journal of Cancer, vol.7, issue.5, pp.643-53, 2004.
DOI : 10.1002/ijc.11566

W. Roth and M. Weller, Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives, Cellular and Molecular Life Sciences (CMLS), vol.56, issue.5-6, pp.5-6, 1999.
DOI : 10.1007/s000180050447

J. H. Sampson and G. E. Archer, Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma, Seminars in Immunology, vol.20, issue.5, pp.267-75, 2008.
DOI : 10.1016/j.smim.2008.04.001

D. Saunders and K. Lucas, Dendritic Cell Development in Culture from Thymic Precursor Cells in the Absence of Granulocyte/Macrophage Colony-stimulating Factor, Journal of Experimental Medicine, vol.184, issue.6, 1996.
DOI : 10.1084/jem.184.6.2185

J. J. Tzeng and R. F. Barth, Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors, Cancer Res, vol.51, issue.9, pp.2373-2381, 1991.

A. J. Wong and J. M. Ruppert, Structural alterations of the epidermal growth factor receptor gene in human gliomas., Proceedings of the National Academy of Sciences, vol.89, issue.7, pp.2965-2974, 1992.
DOI : 10.1073/pnas.89.7.2965

J. M. Adams and A. Strasser, Is Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones?, Cancer Research, vol.68, issue.11, pp.4018-4039, 2008.
DOI : 10.1158/0008-5472.CAN-07-6334

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.465.7556

E. Allard and F. Hindre, 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas, European Journal of Nuclear Medicine and Molecular Imaging, vol.112, issue.10, pp.1838-1884, 2008.
DOI : 10.1007/s00259-008-0735-z

URL : https://hal.archives-ouvertes.fr/inserm-00343438

E. Allard and C. Passirani, Convection-enhanced delivery of nanocarriers for the treatment of brain tumors, Biomaterials, vol.30, issue.12, pp.2302-2320, 2009.
DOI : 10.1016/j.biomaterials.2009.01.003

L. Apetoh and F. Ghiringhelli, Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9, pp.1050-1059, 2007.
DOI : 10.1038/nm1622

URL : https://hal.archives-ouvertes.fr/hal-00316924

S. Ballot and N. Noiret, 99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution, European Journal of Nuclear Medicine and Molecular Imaging, vol.242, issue.5, pp.602-609, 2006.
DOI : 10.1007/s00259-005-0007-0

URL : http://doi.org/10.1007/s00259-005-0007-0

S. Bao and Q. Wu, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.8, issue.7120, pp.756-60, 2006.
DOI : 10.1038/nature05236

R. F. Barth and B. Kaur, Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas, Journal of Neuro-Oncology, vol.10, issue.Suppl 1, pp.299-312, 2009.
DOI : 10.1007/s11060-009-9875-7

D. D. Bigner and M. T. Brown, Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results., Journal of Clinical Oncology, vol.16, issue.6, pp.2202-2214, 1998.
DOI : 10.1200/JCO.1998.16.6.2202

L. Bodei and M. Cremonesi, Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.31, issue.7, pp.1038-1084, 2004.
DOI : 10.1007/s00259-004-1571-4

S. D. Caruthers and S. A. Wickline, Nanotechnological applications in medicine, Current Opinion in Biotechnology, vol.18, issue.1, pp.26-30, 2007.
DOI : 10.1016/j.copbio.2007.01.006

P. J. Coates and J. K. Rundle, Indirect Macrophage Responses to Ionizing Radiation: Implications for Genotype-Dependent Bystander Signaling, Cancer Research, vol.68, issue.2, pp.450-456, 2008.
DOI : 10.1158/0008-5472.CAN-07-3050

J. E. Dancey and F. A. Shepherd, Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres, J Nucl Med, vol.41, issue.10, pp.1673-81, 2000.

E. Deutsch and K. Libson, The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine, International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, vol.13, issue.4, pp.465-77, 1986.
DOI : 10.1016/0883-2897(86)90027-9

M. Diehn and M. F. Clarke, Cancer Stem Cells and Radiotherapy: New Insights Into Tumor Radioresistance, JNCI Journal of the National Cancer Institute, vol.98, issue.24, pp.1755-1762, 2006.
DOI : 10.1093/jnci/djj505

E. Garcion and A. Lamprecht, A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats, Molecular Cancer Therapeutics, vol.5, issue.7, pp.1710-1732, 2006.
DOI : 10.1158/1535-7163.MCT-06-0289

URL : https://hal.archives-ouvertes.fr/hal-00358958

B. Heurtault and P. Saulnier, A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharmaceutical Research, vol.19, issue.6, pp.875-80, 2002.
DOI : 10.1023/A:1016121319668

B. T. Hsieh and J. F. Hsieh, Rhenium-188-labeled DTPA: a new radiopharmaceutical for intravascular radiation therapy, Nuclear Medicine and Biology, vol.26, issue.8, pp.967-72, 1999.
DOI : 10.1016/S0969-8051(99)00074-8

E. Ishikawa and K. Tsuboi, X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions, International Journal of Radiation Oncology*Biology*Physics, vol.59, issue.5, pp.1505-1517, 2004.
DOI : 10.1016/j.ijrobp.2004.04.046

L. M. Kulik and B. Atassi, Yttrium-90 microspheres (TheraSphere??) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation, Journal of Surgical Oncology, vol.29, issue.7, pp.572-86, 2006.
DOI : 10.1002/jso.20609

W. Y. Lau and S. Ho, Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres, International Journal of Radiation Oncology*Biology*Physics, vol.40, issue.3, pp.583-92, 1998.
DOI : 10.1016/S0360-3016(97)00818-3

A. Merlo and O. Hausmann, Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas, Clin Cancer Res, vol.5, issue.5, pp.1025-1058, 1999.

A. Paillard and F. Hindre, The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability, Biomaterials, vol.31, issue.29, pp.7542-54, 2010.
DOI : 10.1016/j.biomaterials.2010.06.024

D. A. Reardon and G. Akabani, Salvage Radioimmunotherapy With Murine Iodine-131???Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results, Journal of Clinical Oncology, vol.24, issue.1, pp.115-137, 2006.
DOI : 10.1200/JCO.2005.03.4082

J. N. Rich, Cancer Stem Cells in Radiation Resistance, Cancer Research, vol.67, issue.19, pp.8980-8984, 2007.
DOI : 10.1158/0008-5472.CAN-07-0895

M. Ropolo and A. Daga, Comparative Analysis of DNA Repair in Stem and Nonstem Glioma Cell Cultures, Molecular Cancer Research, vol.7, issue.3, pp.383-92, 2009.
DOI : 10.1158/1541-7786.MCR-08-0409

W. Roth and M. Weller, Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives, Cellular and Molecular Life Sciences (CMLS), vol.56, issue.5-6, pp.5-6, 1999.
DOI : 10.1007/s000180050447

R. Salem and R. J. Lewandowski, Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival, Journal of Vascular and Interventional Radiology, vol.16, issue.12, pp.1627-1666, 2005.
DOI : 10.1097/01.RVI.0000184594.01661.81

W. R. Schabitz and C. Berger, Effect of Brain-Derived Neurotrophic Factor Treatment and Forced Arm Use on Functional Motor Recovery After Small Cortical Ischemia, Stroke, vol.35, issue.4, pp.992-999, 2004.
DOI : 10.1161/01.STR.0000119754.85848.0D

R. Stupp and W. P. Mason, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-96, 2005.
DOI : 10.1056/NEJMoa043330

S. Vinchon-petit and D. Jarnet, External irradiation models for intracranial 9L glioma studies, Journal of Experimental & Clinical Cancer Research, vol.29, issue.1, p.142, 2010.
DOI : 10.1186/1756-9966-29-142

URL : http://doi.org/10.1186/1756-9966-29-142

S. Vinchon-petit and D. Jarnet, In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy, Journal of Neuro-Oncology, vol.28, issue.2, 2009.
DOI : 10.1007/s11060-009-0012-4

C. Marsac and C. Goussault, Technologies et Ingienerie de la Santé (5 semaines): - " Evaluation de la réponse immunitaire périphérique après radiothérapie interne nanovectorisée dans un modèle de gliome, Encadrement: * Encadrement d'étudiants en Master 1 Sciences Dosage des cytokines Interleukine-2 et Interferon-? après radiothérapie interne dans un modèle de gliome chez le rat

C. Belloche and E. Brocard, Animal (14 semaines): - " Caractérisation de la réponse immunitaire induite par la radiothérapie interne nanovectorisée dans un modèle de gliome, Etude de la stimulation du système immunitaire après radiothérapie interne nanovectorisée associée à une vaccination dans un modèle de gliome

. Feb, Epub Nov 12 -The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats, pp.1560-732010

C. Vanpouille, F. Lacoeuille, E. Garcion, L. Lemaire, F. Bouchet et al., Radiothérapie interne fractionnée à l'aide des nanocapsules lipidiques chargées en rhénium-188 dans un modèle de glioblastome de rat -47ème, 2009.

C. Vanpouille, F. Lacoeuille, J. Roux, C. Aubé, F. Oberti et al., Internal radiation with 188Re-loaded lipid nanocapsules in a rat hepatocellular carcinoma -1srt TARCC international Workshop on targeted radionuclide therapyAdvances in targeted radionuclide therapy, 2009.

C. Vanpouille, F. Lacoeuille, J. Roux, C. Aubé, F. Oberti et al., Hindré F. -Injection intra-artérielle de nanocapsules lipidiques chargées en rhénium-188, pour le traitement du carcinome hépatocellulaire chez le rat -47ème Colloque de Médecine Nucléaire de Langue Française, pp.9-12, 2009.

C. Vanpouille, F. Lacoeuille, E. Garcion, L. Lemaire, F. Bouchet et al., Stereotaxic injections of 188-Re loaded nanocapsules as fractionated internal radioation in a rat glioblastoma model -1srt TARCC international Workshop on targeted radionuclide therapyAdvances in targeted radionuclide therapy, 2009.

C. Vanpouille, F. Lacoeuille, J. Roux, C. Aubé, F. Oberti et al., -Intra-arterial injection of lipid nanocapsules loaded with rhenium-188 for the radiotherapy of hepatocellular carcinomas in rats. ? New trends in Molecular Imaging and Nuclear Medicine, Award « Young Investigator award, pp.14-2009
URL : https://hal.archives-ouvertes.fr/hal-00443488

C. Vanpouille, F. Lacoeuille, J. Roux, C. Aubé, F. Oberti et al., Hindré F. ? Administration of 188 Re-loaded nanocapsules into the hepatic artery involves neoangiogenesis alterations in a rat hepatocellular carcinoma model. -Targeting and Imaging of the Tumor Microenvironment from the 23rd to 26th of, 2009.

C. Vanpouille, E. Garcion, F. Lacoeuille, L. Lemaire, N. Lepareur et al., Hindré F. ? Evaluation of immune responses after nanovectorized internal radiotherapy for glioblastomas, World Molecular Congress, 2010.

C. Vanpouille, E. Garcion, F. Lacoeuille, L. Lemaire, N. Lepareur et al., Hindré F. ? Evaluation of immune responses after nanovectorized internal radiotherapy for glioblastomas. ? Biology of ionizing radiation from the 22nd to 25th of, 2010.

C. Vanpouille, E. Garcion, F. Lacoeuille, N. Lepareur, L. Jeune et al., Hindré F. ? Nanovectorized internal radiation therapy in a glioblastoma rat model. ? EANM'10, Annual Congress of the European Association of Nuclear Medicine, pp.9-13, 2010.